Histoplasmosis in HIV-positive patients in Ceará, Brazil: Clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 106, Issue 8, 2012, Pages 484-488

  Brilhante, Raimunda S N ^a   Fechine, Maria A B ^a   Mesquita, Jacó R L ^c   Cordeiro, Rossana A ^a   Rocha, Marcos F G ^a,b   Monteiro, André J ^a   Lima, Rita A C ^a   Caetano, Érica P ^a   Pereira, Juliana F ^a   Castelo Branco, Débora S C M ^a   Camargo, Zoilo P ^d   Sidrim, José J C ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

^c Hospital São José   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AIDS; Antifungal susceptibility; Brazil; Epidemiology; Histoplasma capsulatum; Histoplasmosis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; CREATININE; FLUCONAZOLE; HEMOGLOBIN; ITRACONAZOLE; LACTATE DEHYDROGENASE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BRAZIL; BROTH DILUTION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; EPIDEMIOLOGY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; KIDNEY FUNCTION; LIVER FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; THROMBOCYTE COUNT; YEAST;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; ITRACONAZOLE; L-LACTATE DEHYDROGENASE; MALE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

AJELLOMYCES CAPSULATUS;

EID: 84863563964     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1016/j.trstmh.2012.05.003     Document Type: Article

References (28)

1. Baddley J.W., Sankara I.R., Rodriguez J.M., Pappas P.G., Many W.J.J. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn Microbiol Infect Dis 2008, 62:151-156.
2. Wheat L.J., Chetchotisakd P. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis 2000, 30:877-881.
3. Huber F., Nacher M., Aznar C., et al. AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS 2008, 22:1047-1053.
4. Couppie P., Sobesky M., Aznar C., et al. Histoplasmosis and acquired immunodeficiency syndrome: A study of prognostic factors. Clin Infect Dis 2004, 38:134-138.
5. Wheat L.J., Freifeld A.G., Kleiman M.B., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.
6. Oliveira F.M., Unis G., Severo L.C. An outbreak of histoplasmosis in the city of Blumenau, Santa Catarina [in Portuguese]. J Bras Pneumol 2006, 32:375-378.
7. Chang M.R., Taira L.C., Paniago A.M.M., Taira D.L., Cunha R.V., Wanke B. Study of 30 cases of histoplasmosis observed in the Mato Grosso do Sul State, Brazil. Rev Inst Med Trop São Paulo 2007, 49:37-39.
8. Mora D.J., Santos C.T.B., Silva-Vergara M.L. Disseminated histoplasmosis in acquired immunodeficiency syndrome patients in Uberaba, MG, Brazil. Mycoses 2007, 51:136-140.
9. Daher E.F., Barros F.A.S., Silva G.B.J., et al. Risk factors for death in acquired immunodeficiency syndrome-associated disseminated histoplasmosis. Am J Trop Med Hyg 2006, 74:600-603.
10. Brilhante R.S.N., Fechine M.A.B., Cordeiro R.A., et al. In vitro effect of sulfamethoxazole-trimethoprim against Histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother 2010, 54:3978-3979.
11. Centers for Disease Control and Prevention (CDC). WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. [accessed 5 May 2011]. http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf.
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. 2nd ed. NCCLS document M27-A2. Wayne, PA: NCCLS; 2002.
13. Cordeiro R.A., Brilhante R.S.N., Rocha M.F.G., et al. In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from northeast Brazil. Mycopathologia 2006, 161:21-26.
14. Barnett D., Walker B., Landay A., Denny T.N. CD4 immunophenotyping in HIV infection. Nat Rev Microbiol 2008, 6:7-15.
15. Cermenõ J.R., Cermenõ J.J., Hernandez I., et al. Histoplasmine and paracoccidiodine epidemiological study in Upata, Boli{dotless}var state, Venezuela. Trop Med Int Health 2005, 10:216-219.
16. Brazilian Ministry of Health. Epidemiological Bulletin - AIDS and STD. [in Portuguese]. Brazil: Ministério da Saúde; 2010.
17. Daher E.F., Silva G.B.J., Barros F.A., et al. Clinical and laboratory features of disseminated histoplasmosis in HIV patients from Brazil. Trop Med Int Health 2007, 12:1108-1115.
18. Karimi K., Wheat J., Connoly P., et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis 2002, 186:1655-1660.
19. Durkin M.M., Connolly P.A., Karimi K., et al. Pathogenic differences between North American and Latin American strains of Histoplasma capsulatum var. capsulatum in experimentally infected mice. J Clin Microbiol 2004, 42:4370-4373.
20. Andreu C.M., León A.M., Medina Y.E., Machín G.M., Lancha M.R., Zaragozi M.T. In vitro susceptibility of Histoplasma capsulatum to amphotericin B, ketoconazole, itraconazole and fluconazole [in Spanish]. Rev Cubana Med Trop 2003, 55:76-82.
21. Li R., Ciblak M.A., Nordoff N., Pasarell L., Warnock D.W., McGinnis M.R. In vitro activities of voriconazole, itraconazole, and amphotericin b against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000, 44:1734-1736.
22. Polak A.M., Dixon D.M. Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49858) against Histoplasma capsulatum var. capsulatum in vitro and in vivo. Mykosen 1987, 30:186-194.
23. Wheat L.J., Connolly P., Smemeda M., et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006, 56:1235-1239.
24. LeMonte A.M., Washum K.E., Smedema M.L., Schnizlein-Bick C., Kohler S.M., Wheat L.J. Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. J Infect Dis 2000, 182:545-550.
25. Wheat L.J., Cloud G., Johnson P.C., et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother 2001, 45:2354-2357.
26. Loeffler J., Stevens D.A. Antifungal drug resistance. Clin Infect Dis 2003, 36:S31-S41.
27. Freifeld A., Proia L., Andes D., et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009, 53:1648-1651.
28. Kohler S., Wheat L.J., Connolly P., et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000, 44:1850-1854.